851528-10-4
Chemical Structure
N-Oxide Lidocaine-d10
- CAS No.: 851528-10-4
- Formula:C14H12D10N2O2
- Molecular Weight:260.40
IUPAC Name: N-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-N-(ethyl-d5)ethan-1-amine oxide-d5
InChIKey: YDVXPJXUHRROBA-JKSUIMTKSA-N
SMILES: N(C(CN(C(C([2H])([2H])[2H])([2H])[2H])(C(C([2H])([2H])[2H])([2H])[2H])=O)=O)C1=C(C)C=CC=C1C
Biological Activity: N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Oxide Lidocaine-d10 | N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lignocaine N-oxide | 99.92% | Lignocaine N-oxide (Lidocaine N-oxide) is a hypoxia-activated prodrug of lidocaine (HY-B0185). Lignocaine N-oxide exerts exactly the same sodium current-blocking effect as lidocaine only when it is converted to lidocaine under ischemic conditions. Lignocaine N-oxide possesses antiarrhythmic activity against ischemia-induced ventricular fibrillation. Lignocaine N-oxide can be used in studies related to ischemia-induced ventricular fibrillation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11. [Content Brief]
